Hormetic Stress Biohacking Type 1 Diabetes CGM

Image
Photo: Unsplash.com Medical Disclaimer : The content on this blog is purely for informational purposes only. For medical advice, diagnosis and treatment, consult your doctor. The ultimate goal for anyone living with Type 1 Diabetes (T1D) is stability. You want fewer spikes, fewer crashes, and more time spent in your target blood sugar range. Read more on blood sugar spike . For years, standard medical advice focused purely on matching insulin doses to carbohydrate intake. While this foundational math is necessary, it often leaves people riding a frustrating blood sugar roller coaster. Today, a new wave of tech-savvy individuals is looking beyond the traditional playbook. They are combining the principles of biohacking, the physiological benefits of hormetic stress, and the real-time data of Continuous Glucose Monitors (CGMs) to transform how they manage their health. This approach does not replace insulin. Instead, it aims to make the body more resilient, predictable, and res...

Insulin Out-of-Pocket Costs Reduction in Medicare

Insulin injection. Photo: Courtesy of Sweet Life/Unsplash.com


Medical Disclaimer: This article is for informational purposes only. For medical advice and diagnosis, consult your doctor.


A study published in JAMA found that the out-of-pocket (OOP) cost of insulin decreased significantly among Medicare beneficiaries not receiving low-income subsidies from 2019 to 2023 in the United States. 

The percentage of beneficiaries paying $35 or less for a 30-day supply of insulin increased from 48% to 75%, with the mean OOP cost decreasing from $50.87 to $21.98 (a 55.8% relative reduction).

The study analyzed data from 3.8 million Medicare Part D beneficiaries and found that insulin costs declined nationwide, but remained highest in rural Midwest states. In 2023, the mean OOP cost for a 30-day supply ranged from $10.36 in Washington, DC, to $31.09 in Minnesota.

However, about 25% of beneficiaries still paid more than $35 for a 30-day supply in 2023, often due to non-prorated claims for quantities not matching 30-day intervals. The researchers suggest that prorating OOP costs to match the Inflation Reduction Act limit could further reduce costs.

The Inflation Reduction Act (IRA) has made significant changes to insulin affordability for Medicare beneficiaries. As of January 2023, Medicare beneficiaries pay no more than $35 per month for insulin, with no deductible applied. This cap applies to all types of insulin, including those covered under Medicare Part B for use in insulin pumps, starting July 2023.

Key Benefits:

  • Insulin Price Cap: $35 monthly cap on insulin costs for Medicare beneficiaries
  • No Deductible: Insulin costs are exempt from deductible payments
  • Expanded Coverage: Applies to all Medicare Part D plans and certain Part B insulin pumps

An estimated 1.5 million Medicare beneficiaries using insulin would have saved $734 million in Part D and $27 million in Part B if these caps had been in effect in 2020, averaging $500 savings per beneficiary.


Read more

https://jamanetwork.com/journals/jama/fullarticle/

Comments

Popular posts from this blog

The Impressive Health Benefits of Pumpkin Seeds

The Grave Consequences of Attacking Health Sites in Iran

Why Gastric Ulcer Patients Should Avoid Tomatoes and Tomato-Based Products